6-Fluoro-5-(4-t-butyloxycarbonylpiperazin-1-yl)-2-mercapto-1H-benzimidazole | 216883-21-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 6-Fluoro-5-(4-t-butyloxycarbonylpiperazin-1-yl)-2-mercapto-1H-benzimidazole
• 英文别名: tert-butyl 4-(6-fluoro-2-sulfanylidene-1,3-dihydrobenzimidazol-5-yl)piperazine-1-carboxylate
• CAS: 216883-21-5
• 化学式: C₁₆H₂₁FN₄O₂S
• 分子量: 352.433
• InChiKey: LSINYKKUIDNSBN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  88.9
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  6-Fluoro-5-(4-t-butyloxycarbonylpiperazin-1-yl)-2-mercapto-1H-benzimidazole 、 alkaline earth salt of/the/ methylsulfuric acid 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 2-[(2,3-dichlorophenyl)methylsulfanyl]-6-fluoro-5-piperazin-1-yl-1H-benzimidazole
  参考文献：
  名称：

  Identification of novel benzimidazole series of potent and selective ORL1 antagonists

  摘要：

  Structure-activity studies on benzimidazole lead 1 obtained from library screening led to the discovery of potent and selective ORL1 antagonist 28, 5-chloro-2-[(1-ethyl-1-methylpropyl) thio]-6-[4-(2-hydroxyethyl) piperazin-1-yl]-1H-benzimidazole, which is structurally distinct from conventional non-peptide antagonists known to date. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.04.054
• 作为产物：
  描述：

  二硫化碳 、 tert-butyl 4-(4,5-diamino-2-fluorophenyl)piperazine-1-carboxylate 在 sodium hydroxide 作用下， 以 乙醇 、 水 为溶剂， 生成 6-Fluoro-5-(4-t-butyloxycarbonylpiperazin-1-yl)-2-mercapto-1H-benzimidazole
  参考文献：
  名称：

  Identification of novel benzimidazole series of potent and selective ORL1 antagonists

  摘要：

  Structure-activity studies on benzimidazole lead 1 obtained from library screening led to the discovery of potent and selective ORL1 antagonist 28, 5-chloro-2-[(1-ethyl-1-methylpropyl) thio]-6-[4-(2-hydroxyethyl) piperazin-1-yl]-1H-benzimidazole, which is structurally distinct from conventional non-peptide antagonists known to date. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.04.054

文献信息

• Benzimidazole derivatives
  申请人：——

  公开号：US20040044056A1

  公开（公告）日：2004-03-04

  This invention relates to the compounds represented by a general formula [I]: 1 [in which A 1 and A 2 represent optionally fluorine-substituted methine or the like; B represents halogen, cyano, lower alkyl or the like; D represents optionally substituted heterocyclic group or the like; and G represents C 3 -C 20 aliphatic group such as alicyclic group]. These compounds inhibit nociceptin activities due to their high affinity to nociceptin receptor, and are useful as analgesic, antiobestic, corebral function improver, drugs for treatment of alzheimer's disease and dementia, remedies for schizophrenia and neurodegenerative diseases, antidepressant, remedies for diabetes insipidus, polyuria, hypotension and so on.

  本发明涉及由一般式[I]表示的化合物：1[其中，A1和A2表示选择性氟代甲基或类似物；B表示卤素，氰基，低碳烷基或类似物；D表示选择性取代的杂环基团或类似物；G表示C3-C20脂肪族基团，例如脂环族基团]。这些化合物由于对痛觉受体具有高亲和力而抑制了痛觉肽活性，并且可用作镇痛剂，抗肥胖剂，脑功能改善剂，治疗阿尔茨海默病和痴呆症的药物，治疗精神分裂症和神经退行性疾病的药物，抗抑郁剂，治疗尿崩症，多尿症，低血压等的药物。
• Benzimidazole derivatives as antiulcer agents, process for their
  申请人：Dr. Reddy's Research Foundation

  公开号：US06051570A1

  公开（公告）日：2000-04-18

  This invention particularly relates to novel pyridylmethylsulfinyl benzimidazole represented by the general formula (I), its tautomers, its derivatives, its analogs, its stereoisomers, its polymorphs, its pharmaceutically acceptable salts, its pharmaceutically acceptable solvates and pharmaceutical compositions containing them and the use thereof. ##STR1## The present invention also relates to a process for the preparation of the above said novel pyridylmethylsulfinyl benzimidazoles and pharmaceutical compositions containing them.

  本发明特别涉及一种由通式（I）表示的新型吡啶甲基亚磺酰基苯并咪唑，其互变异构体、衍生物、类似物、立体异构体、多晶形态、药学上可接受的盐、药学上可接受的溶剂和含有它们的制药组合物以及它们的使用。 ##STR1## 本发明还涉及上述新型吡啶甲基亚磺酰基苯并咪唑和含有它们的制药组合物的制备方法。
• BENZIMIDAZOLE DERIVATIVES
  申请人：BANYU PHARMACEUTICAL CO., LTD.

  公开号：EP1342717A1

  公开（公告）日：2003-09-10

  This invention relates to the compounds represented by a general formula [I]:    [in which A1 and A2 represent optionally fluorine-substituted methine or the like; B represents halogen, cyano, lower alkyl or the like; D represents optionally substituted heterocyclic group or the like; and G represents C3-C20 aliphatic group such as alicyclic group]. These compounds inhibit nociceptin activities due to their high affinity to nociceptin receptor, and are useful as analgesic, antiobestic, corebral function improver, drugs for treatment of alzheimer's disease and dementia, remedies for schizophrenia and neurodegenerative diseases, antidepressant, remedies for diabetes insipidus, polyuria, hypotension and so on.

  本发明涉及通式[I]所代表的化合物： [其中 A1 和 A2 代表任选氟取代的甲基或类似物；B 代表卤素、氰基、低级烷基或类似物；D 代表任选取代的杂环基团或类似物；G 代表 C3-C20 脂肪族基团，例如脂环族基团]。这些化合物由于与痛觉素受体的高亲和力而抑制痛觉素的活性，可用作镇痛剂、抗镇静剂、改善大脑核心功能的药物、治疗老年痴呆症和痴呆症的药物、治疗精神分裂症和神经退行性疾病的药物、抗抑郁剂、治疗糖尿病、多尿、低血压等。
• NOVEL BENZIMIDAZOLE DERIVATIVES AS ANTIULCER AGENTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
  申请人：DR. REDDY'S RESEARCH FOUNDATION

  公开号：EP0983263A1

  公开（公告）日：2000-03-08
• US6051570A
  申请人：——

  公开号：US6051570A

  公开（公告）日：2000-04-18